Real-World Effectiveness and Safety of Risankizumab in Adult Patients with Plaque Psoriasis: A 16-Week International Multicenter Retrospective Cohort Study
Restricted accessLetterFirst published online November, 2024
Real-World Effectiveness and Safety of Risankizumab in Adult Patients with Plaque Psoriasis: A 16-Week International Multicenter Retrospective Cohort Study
GordonKBStroberBLebwohlM, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392:650-661.
2.
BlairHA. Risankizumab: a review in moderate to severe plaque psoriasis. Drugs. 2020;80:1235-1245.
3.
EgebergABryldLESkovL. Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2019;81:173-178.
4.
LytvynYMuftiAZaarouraH, et al. Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: a 16-week Canadian retrospective multicenter cohort study. JAAD Int2022;6:3-5.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
